Podcasts about clinical trials

We love to hear from our listeners. Send us a message.In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials. They pinpoint key friction points, such as delayed referrals, unpredictable vein-to-vein timelines, and burdensome long-term follow-up, while sharing actionable strategies for simplification. These strategies range from upstream trial design and streamlined consent processes to standardized logistics, hybrid monitoring models, honest risk communication, and engaging patients as true partners in real-world evidence generation.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this episode of 10X Growth Strategies, host Arthi Vijayaraghavan sits down with Lakshmi Nair — drug development scientist and genetic engineering researcher — to unpack the science, promise, and responsibility behind CRISPR and gene editing. Drawing from her journey across academia and biomedical research, Lakshmi explains how CRISPR transformed genetic engineering from slow, uncertain experimentation into precise DNA editing — and why that leap could reshape medicine, cancer treatment, and hereditary disease forever. From transgenic models and drug development to the realities of scientific failure and perseverance, the conversation reveals what modern biomedical innovation truly looks like behind the scenes. The episode explores the ethical frontier of gene editing — germline modification, designer traits, disability vs identity, and who gets to decide what should be “fixed” in humans. The discussion also connects CRISPR with AI-driven research, data-intensive clinical trials, and the global scientific ecosystem that turns basic research into life-saving therapies. From biohacking and scientific curiosity to regulation, responsibility, and the future of humanity, this is a thoughtful, deeply grounded conversation on what it means to hold the power to rewrite life itself. A fascinating listen for technologists, policymakers, investors, and anyone curious about where biology, AI, and human evolution intersect. ⸻ 00:00 – Introduction & Lakshmi's Background 02:00 – Why CRISPR Changed Genetic Engineering 06:00 – Scientific Journeys, Curiosity & Upbringing 12:00 – CRISPR Explained for Non-Biologists 18:30 – Medical Applications: Cancer & Genetic Disease 23:30 – Scientific Collaboration & Peer Review 26:30 – Biohacking & Democratizing Biology 30:00 – Gene Editing Ethics & Germline Debate 36:00 – Identity, Disability & Human Choice 40:00 – From Lab Research to Drug Development 45:00 – AI in Clinical Trials & Biomedical Data 50:00 – Future of Gene Editing & Responsibility 54:00 – Closing Reflections

Send a textBen and Daphna review a randomized controlled trial published in The Journal of Pediatrics by Dr. Ariel Salas and colleagues at UAB. The study investigates whether early high-dose vitamin D supplementation (800 IU/day starting day 1) in extremely preterm infants reduces the incidence of Bronchopulmonary Dysplasia (BPD) compared to standard care (starting day 14). The hosts discuss the physiologic rationale linking vitamin D to lung development, the use of impulse oscillometry to measure lung mechanics, and the secondary findings regarding metabolic bone disease. They explore why the "physiologic rationale" doesn't always translate to clinical significance.----Early Vitamin D Supplementation in Infants Born Extremely Preterm and Fed Human Milk: A Randomized Controlled Trial. Salas AA, Argent T, Jeffcoat S, Tucker M, Ashraf AP, Travers CP.J Pediatr. 2025 Dec;287:114754. doi: 10.1016/j.jpeds.2025.114754. Epub 2025 Jul 24.PMID: 40714046 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Is chronic babesiosis finally getting the scientific attention it deserves?In this episode of Integrative Lyme Solutions, Dr. K sits down with Dr. Geoff Dow, CEO & President of Sixty Degrees Pharmaceuticals, to discuss a groundbreaking clinical trial targeting chronic babesiosis — a common and often overlooked Lyme co-infection. Originally developed for malaria prevention, the drug Tafenoquine (brand name Kodatef®) is now being studied for its potential to treat persistent Babesia infections and Lyme-related fatigue.They explore the science behind red blood cell parasites, how Babesia differs from malaria, why chronic babesiosis remains controversial, and what makes this new trial the first FDA-reviewed IND study focused on chronic disease. If you or a loved one struggle with Lyme-related fatigue, relapsing babesiosis, or limited treatment options, this conversation offers cautious optimism and a closer look at the future of targeted therapies.Key Takeaways:0:00 Introduction3:10 From Malaria Drug Development to Lyme Co-Infections6:45 How Babesia Infects Red Blood Cells and Causes Fatigue10:40 Why Chronic Babesiosis Is Still Controversial14:50 No FDA-Approved Drugs Specifically for Babesiosis18:30 New Clinical Trials for Chronic and Relapsing Babesiosis24:00 Measuring Fatigue as a Primary Endpoint in Chronic DiseaseResources Mentioned:Sixty Degrees Pharmaceuticals - https://www.sixtydegreespharma.comKodatef® (Tafenoquine) Information - Available via company website aboveMount Sinai (Clinical Trial Site) - https://www.mountsinai.orgYale Babesiosis Case Series (Referenced Study) - https://medicine.yale.eduMedical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. _______________________________The Karlfeldt Center offers the most cutting-edge and comprehensive Lyme therapies. To schedule a Free 15-Minute Discovery Call with a Lyme Literate Naturopathic Doctor at The Karlfeldt Center, call 208-338-8902 or email info@TheKarlfeldtCenter.comCheck out Dr. K's Ebook: Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery here: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lymeUse the code LYMEPODCAST for a 100% off discount!

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Health Affairs' Rob Lott interviews So-Yeon Kang of Georgetown University about her recent paper exploring trends in biopharmaceutical clinical trials after The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs. Order the January 2026 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast

Robert's LinkedIn: https://www.linkedin.com/in/robert-s-goldman/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

From Music to Medicine: Rethinking Clinical Trials, AI, and Real-World Evidence On this episode Gil and Gregg welcome Amir Lahav, MD, ScD, founder and CEO of SkyMedAI and curator of the Digital Health AI Innovation Summit in Boston. Dr. Lahav traces his unlikely path from working musician to Harvard Medical School faculty, Pfizer rare-disease innovator, and now advisor to digital health and life sciences companies. The conversation explores how music-driven neurorehabilitation helped stroke survivors regain motor function, why traditional snapshot-based clinical trials are “embarrassingly wrong” for real-world patients, and how AI and wearables can turn continuous data into earlier detection and more humane care. Lahav also warns about overconfident, under-validated AI and argues that the most successful health companies by 2030 will be those that know when not to use AI. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this episode, she and Niklas explore why drug development takes over a decade, why only ~10% of drugs reach approval, and how clinical trials have become one of the biggest bottlenecks to biomedical progress.They unpack how incentives distort which diseases get treated, why surrogate endpoints matter, and how off-label use, real-world data, and even “bro science” reveal gaps in the current system.They also cover: • Clinical evolution and iterative human testing • Regulatory opacity and open-sourcing FDA filings • Australia's faster Phase 1 model • Human challenge trials and medical freedom • Surrogate endpoints and distorted incentives • Real-world data and off-label discovery • Biotech innovation shifting to China • How better trials unlock biomedical abundanceA conversation for anyone interested in biotech, policy, and the future of drug development. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

Is there evidence that the ketogenic diet can cure schizophrenia?Recent comments from HHS Secretary Robert F. Kennedy Jr. sparked headlines…and controversy. While “cure” isn't the right word, the conversation has brought much-needed attention to an emerging field: metabolic psychiatry.In this video, Dr. Bret Scher breaks down what the science actually shows about ketogenic metabolic therapy as a potential adjunctive treatment for serious mental illness, including schizophrenia, bipolar disorder, and major depressive disorder.You'll learn about:What nutritional ketosis is and why brain energy matters for serious mental illnessHow psychiatric conditions like schizophrenia, bipolar disorder, and major depressive disorder involve underlying metabolic dysfunctionEarly evidence on ketogenic therapy for serious mental illness from Stanford, Edinburgh, and The Ohio State UniversityHow consistent lived experiences aligned with emerging clinical data warrant serious scientific explorationWhat new research is on the wayKetogenic therapy is emerging as a serious metabolic strategy that may expand how we think about treating complex psychiatric conditions. We are now faced with the opportunity to study it rigorously, apply it thoughtfully, and ensure patients have access to every tool that could help.

In this episode, Jess and Sarah welcome Dr. Neil Goldenberg to explore the unique challenges and complexities of conducting pediatric clinical trials. The scientists examine the necessity of multi-center studies, ethical considerations specific to research involving children, and the critical physiological differences between pediatric and adult populations that require distinct research approaches. Dr. Goldenberg shares valuable insights from his research experiences, including the KidsDOTT and COVAC-TP trials, while discussing the essential roles of funding and infrastructure in advancing pediatric research. Throughout the conversation, the experts emphasize the importance of collaboration and advocacy in this field. The episode concludes with an optimistic perspective on the future of pediatric clinical research and its potential to improve health outcomes for children. Watch the conversation on YouTube: https://youtu.be/yqS4b3kqHHM (00:00) Intro & Public Health Update (05:33) What's A Health/Science News Item That Caught Your Attention? (07:34) What Is A Multi-Center Study? (09:35) What Protections Are There For Human Subject Clinical Trials? (13:04) Why Is There A Need For Separate Trials For Children Vs Adults? (17:42) Examples of Dr. Goldenberg's Trials (24:50) What Does It Mean If Pediatric Trials Don't Get Funded? (29:13) Is There Anything We Can Do To Support Pediatric Clinical Trials? (31:51) What's Giving You Hope In Public Health And Science Right Now? https://www.hopkinsmedicine.org/all-childrens-hospital/ https://www.linkedin.com/in/neil-goldenberg-md-phd-59226b63 Disclaimer from Dr. Goldenberg: "The opinions I share during this conversation are my own and do not necessarily reflect the official positions or policies of my employer." ----------------------------------------------------------------------------------------------------------------------- Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr Peter Connelly narrates his blog written for Dementia Researcher. In this blog, Peter compares academically led and commercially sponsored clinical trials, outlining how they differ in goals, recruitment expectations, intensity, monitoring and funding. Drawing on personal experience, he highlights unrealistic recruitment projections, contrasts study cultures, and reflects on the professional rewards and pressures associated with each model. The blog offers practical insight for clinicians considering participation in dementia research. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-two-worlds-of-clinical-trials/ -- Dr Peter Connelly is a retired Old Age Psychiatrist who spent much of his career in Tayside, helping to establish clinical trials for dementia and neuroprogressive disorders in Scotland. Now working with the Scottish Neuroprogressive and Dementia Network, he combines professional insight with personal experience as a former carer. In retirement, he enjoys music, golf, and time with his grandchildren. -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Join our community: https://onelink.to/dementiaresearcher

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tuesday, February 17, 2026 - Week 8   We are flat out, thank you to the team who work full-time on SYNGAP1: VM KAH LP PP & KF.   CLINICAL TRIAL DESIGN We are Angelman-like. (Rett also) https://aesnet.org/abstractslisting/differentiating-key-symptoms-of-angelman-syndrome-as-and-syngap1-via-caregiver-reported-and-us-claims-data-to-understand-differences-between-how-providers-and-caregivers-view-impacts-on-patient-care Dravet or Angelman?  Phase 1/2 is when we try it all.  EEGs and NHS help with this effort.   BIOSAMPLES & EEGs! Biorepository needs more samples.  Check out the list and map here https://combinedbrain.org/roadshow/ and contribute both blood & EEGs.  The data and research we do with these samples is invaluable.  Let us know if you are going, email our CSO@curesyngap1.org.   (Stay tuned for another exciting device study…)   NATURAL HISTORY STUDY Sign up for Citizen Health cureSYNGAP1.org/Citizen and ProMMiS cureSYNGAP1.org/ProMMiS NHS Survey in English: https://curesyngap1.org/SurveyProMMiS & Spanish: https://curesyngap1.org/encuestaProMMiS Latest Pod on NHS: https://youtu.be/7W38uWKBIAw?si=lCrffwMXidmYWz7t   FUNDRAISING - SPRINT4SYNGAP Sprint is April 25 - our calendar page - cureSYNGAP1.org/Sprint - has all the information in the following links: set up your team - cureSYNGAP1.org/Sprint26 resource guide for your event - cureSYNGAP1.org/S4SGuide webinar #99 to help get you started - cureSYNGAP1.org/S4S25   Also, May 28, San Francisco, CA: cureSYNGAP1.org/SF26 Scramble for Syngap - 5th annual on October 3 in S. Carolina cureSYNGAP1.org/Scramble26   PUBMED Pubmed 2026 is at 9! https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date (Remember we had 18 in all of ‘18) Cool connection to #PraderWilli Syndrome. https://www.linkedin.com/posts/graglia_syngap1-praderwilli-autism-share-7429579885985296385-zuIH   ETC - More warriors cureSYNGAP1.org/Warrior - Dr. Donlin-Asp Press Release cureSYNGAP1.org/PR42 see talk here https://www.youtube.com/watch?v=lR8qcZK-9ro - Bravo Sara Driscol and GeneDx https://www.linkedin.com/posts/genedx_beyondawareforrare-ugcPost-7427763511235248129-QPPL?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAD8f4B7JC4TMss45Q8hrsq5kiceI0Z8HE   SOCIAL MATTERS 4,686 LinkedIn.  https://www.linkedin.com/company/curesyngap1 1,520 YouTube.  https://www.youtube.com/@CureSYNGAP1 11.2k Twitter https://twitter.com/cureSYNGAP1 45k Insta https://www.instagram.com/curesyngap1   $CAMP stock is at $3.85 on 17 Feb. ‘26 https://www.google.com/finance/beta/quote/CAMP:NASDAQ   Like and subscribe to this podcast wherever you listen.  https://curesyngap1.org/podcasts/syngap10/ Episode 199 of #Syngap10 #CureSYNGAP1 #Podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Every clinical setback carries lessons. That’s why Fierce revisits major trial failures each year: not to dwell on disappointment, but to understand what went wrong and what it signals for the road ahead. The 2025 edition of Fierce Biotech’s clinical trial flops report highlights a familiar pattern. Large drugmakers account for a disproportionate share of high-profile misses, reflecting the reality that many of the industry’s most ambitious late-stage programs now sit inside big pharma portfolios. On this episode of "The Top Line," Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the failures that stood out in 2025 and what they suggest about the challenges facing drug development. To learn more about the topics in this episode: 2025's top 10 clinical trial flops Sanofi ousts Paul Hudson after 'bumpy ride,' enlists Merck KGaA CEO to lead the French pharma See omnystudio.com/listener for privacy information.

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

What does it truly mean to see—and how can technology restore one of our most essential human senses? In this episode, Dr. José-Alain Sahel joins Kate O’Neill to reveal the breakthroughs in vision restoration, and how these innovations are shaping the future of human experience. Topics Covered: Optogenetic therapy and vision restoration Artificial retina technology Scientific and patient journey of regaining sight Convergence of AI, neuroscience, and medical devices Philosophy of sight and perception Natural vs. artificial boundaries in biotech Balancing innovation and patient safety Strategies for treating different stages of blindness Meaning and legacy of vision technologies Connect with: Dr. José-Alain SahelThe Eye & Ear Foundation of PittsburghUPMC Enterprises Episode Chapters: 00:00:05 – Welcome to the Tech Humanist Show 00:01:14 – Introduction of Dr. José-Alain Sahel 00:02:29 – 2021 Optogenetic Vision Restoration Breakthrough 00:02:46 – Recent Artificial Retina Breakthrough (2025) 00:03:47 – The First Patient's Experience 00:06:31 – Explaining the Technology: Algae Proteins & Retinal Cells 00:09:00 – Scientific Process: Failures, Persistence, and Progress 00:10:13 – How the Goggles Work 00:11:03 – Training the Brain to Interpret New Visual Input 00:11:24 – The Patient's Story: From Blindness to Seeing Again 00:16:07 – Philosophical Perspective on Sight and Perception 00:20:02 – Measuring Human Experience in Vision Restoration 00:23:26 – Natural vs. Artificial: Ethics and Human Augmentation 00:26:19 – Balancing Innovation with Patient Safety in Clinical Trials 00:29:53 – Complementary Strategies for Blindness Treatment 00:31:34 – Vision, Meaning, and Human Flourishing 00:34:41 – Where to Find More About Dr. Sahel's Work 00:35:49 – Episode Credits & Outro

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send a textIn this episode of Journal Club, Ben and Daphna review a non-inferiority trial from the European Journal of Pediatrics exploring surfactant administration thresholds in preterm neonates. The study, conducted in India, compares a 30% versus 40% FiO2 threshold for babies 26-32 weeks gestational age. The hosts break down the counterintuitive findings regarding respiratory support duration in younger subgroups and discuss the broader implications of using rigid FiO2 heuristics versus individualized patient assessment. They also debate how resource availability influences clinical protocols and the potential benefits of "LISA" (Less Invasive Surfactant Administration) for avoiding intubation.----Higher (40%) versus lower (30%) FiO2 threshold for surfactant administration in preterm neonates between 26 and 32 weeks of gestational age: a non-inferiority randomized controlled trial. Haq MI, Datta V, Bandyopadhyay T, Nangia S, Anand P, Murukesan VM.Eur J Pediatr. 2025 Nov 25;184(12):793. doi: 10.1007/s00431-025-06628-1.PMID: 41288797 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of stories that highlight the dynamic and often challenging landscape of these industries, as they navigate through scientific breakthroughs, strategic collaborations, regulatory hurdles, and market trends.Starting with corporate restructuring, Roche's Genentech has announced significant layoffs, totaling 489 positions in the previous year. This move is part of broader restructuring efforts seen across large pharmaceutical companies like Bayer and Bristol Myers Squibb. The layoffs illustrate the tightening financial and scientific constraints that are influencing pipeline decisions and capital allocation. Companies are facing increasing pressures to maintain credibility while also dealing with economic challenges that impact their strategic directions.On the regulatory front, the U.S. Department of Health and Human Services (HHS) encountered legal setbacks concerning its 340B rebate model pilot program. Following a lawsuit from the American Hospital Association, HHS withdrew notices and application approvals for this initiative. This development indicates a need for more comprehensive public feedback before any future attempts at similar programs are made, highlighting how complex regulatory landscapes can become.Turning to clinical trials, Fierce Biotech identified several significant failures in 2025, underscoring the inherent risks involved in drug development. These setbacks emphasize the importance of robust trial designs and execution strategies to mitigate risks. Meanwhile, Fresenius Kabi and Phlow Corporation have announced a strategic alliance to produce epinephrine injection API in the U.S., aiming to strengthen supply chain resilience—a crucial lesson learned from vulnerabilities exposed during the COVID-19 pandemic.Eli Lilly has made waves with its $2.4 billion acquisition of Orna Therapeutics, marking its entry into the in vivo CAR-T space. This acquisition underscores a growing interest in advanced cell therapies with transformative potential for cancer treatment. Additionally, Lilly has expanded its collaboration with Innovent Biologics through a $350 million upfront payment and milestone payments totaling $8.8 billion, focusing on oncology and immunology. This reflects a shift towards deeper integration in drug development efforts beyond traditional licensing models.Takeda Pharmaceuticals' $1.7 billion AI-driven drug discovery agreement with Iambic Therapeutics highlights the increasing adoption of artificial intelligence to accelerate drug discovery processes. AI's potential to enhance precision medicine approaches is becoming more pronounced as companies seek innovative methods to improve target identification and lead optimization.In market dynamics, Hims & Hers withdrew from launching a generic version of Novo Nordisk's weight loss pill due to regulatory pressures from the FDA. This incident underscores the complex interplay between innovation and compliance that companies must navigate when bringing new therapeutics to market. Additionally, legal actions have been initiated by Novo Nordisk against Hims & Hers over patent infringement claims related to semaglutide—a case highlighting ongoing challenges in patent protection within rapidly evolving drug compounding arenas.Eli Lilly also leveraged the global stage of the Winter Olympics for a campaign drawing parallels between scientific progress and athletic achievement. Such campaigns align with industry efforts to enhance public perception and trust amid ongoing challenges.Overall, while the pharmaceutical and biotech industries face significant challenges—from regulatory hurdles to clinical trial setbacks—there are substantial opportunities for growth driven by technological advancements and strategic collaborations. NaSupport the show

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Clinical trials are the gateway to getting life-saving therapies to patients, yet traditional research methods often create barriers that slow progress and limit participation.Our next guest, Dr. Pamela Tenaerts, is tackling this challenge as Chief Medical Officer of Medable.With more than two decades of clinical research experience, including leadership of the Clinical Trials Transformation Initiative, Pamela possesses a unique perspective bridging rigorous science and digital innovation.Driven by a passion to ensure that evidence-based best practices guide how we transform research, Pamela shares Medable's pioneering vision to decentralize clinical trials and meet patients where they are.Join us to discover how Medable's digital platform is accelerating trials across 70 countries, expanding patient access, and getting effective therapies to people faster. Let's go!Episode Highlights:Evidence First: Always research whether a solution actually works before implementing—assumptions can be wrong.One, One, and One: Medable's vision is to start a study in one day, enroll in one day, and complete in one year.Expanding Access: Decentralized trials help rare disease and rural patients participate without traveling to research sites.AI Integration: Medable uses AI to instantly generate patient questionnaires and automate trial workflows.Finding Trials: Patients need easier ways to discover clinical trials that exist for their conditions.About our Guest:Pamela Tenaerts, MD, is Medable's Chief Medical Officer, and aims to drive advancement of decentralized research methodologies with evidence-based best practices. She brings more than two decades of clinical research experience having previously served as Executive Director of the Clinical Trials Transformation Initiative (CTTI), Director of Clinical Programs at Coaxia, Director of the Clinical Research Center at Sarasota Memorial Hospital, and various other research positions. She can be reached at pamela.tenaerts@medable.com.Links Supporting This Episode: Medable Website: CLICK HEREDr. Pamela Tenaerts LinkedIn page: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website:

Send a textDr. Michael Koren joins Kevin Geddings to talk about what the Super Bowl can teach us about medicine. The doctor discusses on how players get two weeks off to prepare (and heal) for the Super Bowl. He then relates this to a growing trend in investigational medicine where pharmaceutical companies are searching for longer-term medications for blood pressure and other conditions that only need to be taken once a month or less. The hope is that this "time off" from taking medicines will allow for better outcomes. Dr. Koren describes a specific investigational study looking at a potential monthly blood pressure medication and explains that the relaxed schedule may take the pressure off patients who take these medications.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Stop building "interesting" digital health apps that nobody buys. Bruce Hellman (uMotif) joins Jim and Eugene to reveal why "interesting" is the kiss of death for scaling in healthcare. We dive into the pivot from "crushing" civil service bureaucracy to finding "must-have" budgets in Global Pharma and Clinical Trial research. Explore the Mortar Theory of patient data and how to build for the "Citizen Scientist". Always Fun Mentions: Instagram Muscles: Eugene's quest for a 15-second handstand. Dubai Roots: Bruce as the first male born in Sharjah. Essex County: Britain's "finest" county. The Ski-Rep Era: 100+ days of career-building on the slopes. Chapters: 00:00 - Handstands & February Vibes 04:20 - Born in Sharjah 10:45 - The Bureaucracy Burn 17:15 - Meeting a Co-Founder at a Nursery Party 24:00 - Bricks & Mortar: The Data Theory 36:30 - The Pharma Pivot 49:15 - Follow the Money As always - we are meticulously unproduced.

Send us a textUniversity of Maryland School of Medicine (UMSOM) associate professor Sarah M. Kattakuzhy, MD, joins “The UMB Pulse” this month to talk about her research exploring whether semaglutide (a GLP-1 medication widely used for diabetes and weight management) could help reduce cravings and improve outcomes for people with stimulant use disorder.Kattakuzhy, who is also the co-director of the Kahlert Institute for Addiction Medicine at UMSOM, describes the design of the STAC Study, which is evaluating the safety and tolerability of semaglutide in people with cocaine use disorder, including participants with and without HIV, while also tracking secondary outcomes such as changes in drug use and cravings.She also discusses why stimulant use disorders, including cocaine and methamphetamine use disorder, have been especially challenging to treat, and how her work through the University of Maryland, Baltimore community-based research partnerships aims to expand treatment options and reduce stigma around substance use disorders.To learn more about this trial or for referrals, contact Dr. Kattakuzhy at skattakuzhy@ihv.umaryland.edu.00:00 Introduction to Addiction and New Research00:40 Meet Dr. Sarah Kattakuzhy01:45 A Day in the Life of Dr. Kattakuzhy03:57 The Journey to Addiction Research07:40 Exploring Semaglutides for Addiction Treatment12:34 Details of the Clinical Trial20:29 Challenges and Hopes in Addiction Treatment24:31 Collaborations and Future Directions27:39 Final Thoughts and Takeaways32:13 Post-Interview InsightsListen to The UMB Pulse on Apple, Spotify, Amazon Music, and wherever you like to listen. The UMB Pulse is also now on YouTube.Visit our website at umaryland.edu/pulse or email us at umbpulse@umaryland.edu.

In this episode of Moving Medicine Forward, we speak with CTI Founder & CEO Tim Schroeder and Managing Director of Latin America Jaqueline Aguiar about the region's scientific strength, evolving regulatory landscape, exceptional patient retention, and growing role in rare disease and advanced therapies. They share real‑world examples of record‑speed approvals, high‑quality data, and the cultural dynamics that make LATAM a uniquely powerful environment for clinical trials. A must‑listen for anyone involved in global development or curious about the future of research in emerging markets. 01:22 Why LATAM is a strategic hub: scientific capability, cost efficiency, patient diversity, centralized healthcare, and increasingly fast regulatory timelines.03:32 Tim on LATAM's standout strengths — exceptional data quality, major specialty centers, and cost‑effective trial execution.05:15 CTI's expansion in the region: driven by rare disease needs, global sponsor demand, and Jaclyn's leadership building a resilient LATAM infrastructure.08:04 How LATAM supported global studies during COVID‑19and the ongoing complexities of logistics, sample transport, and country‑specific operations.10:11 Significant regulatory acceleration across Brazil, Mexico, Colombia, Peru, and Chile — including

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Paresh Vyas and Andrew Hantel on their research published in this week's issue of Blood. Dr. Vyas discusses his paper, "Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy", which provided new insights as to when and how to intervene to circumvent resistance to AML remission. Dr. Hantel will speak about his paper, "Impact of Modernizing Eligibility Criteria on Enrollment and Representation in AML Clinical Trials". For a real-world cohort of more than 2200 patients with AML, they reported that modernized, safety-based criteria could nearly double trial eligibility, with especially pronounced gains among historically underserved groups.  Both studies highlight how biologic insight and thoughtful trial design can drive more effective, inclusive advances in AML treatment and research. 

In 1599, a family in a small French town claimed that their daughter was possessed by a demon called Beelzebub and, despite daily exorcisms, the demon possessing this woman was staying put. So France's Henri IV set up a royal commission that would try something a little different. The woman would still receive exorcisms, complete with the normal exorcism accoutrements, but with a catch. The priest wouldn't actually be Catholic, the water in the vessel would be ordinary water, and the Latin used wouldn't be religious — it would be from Virgil's famous poem Aeneid. That's because this wasn't actually an exorcism. It was an experiment built on a deceptively simple tool that scientists and doctors still use today to study new medical treatments: a placebo.In this episode, we explore the surprising origins and evolution of one of modern medicine's most important tools: the clinical trial. We follow the development of experimental design across centuries to modern day randomized controlled trials and the debates about their limitations, trying to answer the question, “How do we know whether a treatment truly works?”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. H. Jackson Downey sits down with MedEvidence!™ to give the low-down on keeping your lipoprotein(a) numbers down. Lipoprotein little a, also called Lp(a), is a really, really, really, really, really bad cholesterol that is genetically determined, meaning exercise and diet don't help lower the numbers. Instead, Dr. Downey explains, clinical trials are looking into investigational medications for this bad type of cholesterol. Dr. Downey describes the ins and outs of Lp(a) and how clinical research is our best bet for solutions to this dangerous cholesterol.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

The University of Galway has today launched its new Medical Device Prototype Hub, supported by medical device company Medtronic. The development of the facility is part of the five-year €5 million signature innovation partnership between Medtronic and the University, announced in 2023, which focuses on three pillars: developing the MedTech ecosystem, STEM engagement and research. President of University of Galway, Professor David Burn, said: "The launch of the Medical Device Prototype Hub at University of Galway marks a hugely significant milestone in our signature partnership with Medtronic but it also sends a strong message to all those in the sector and all those who are driving innovation – University of Galway is creating the ecosystem in which our partners in research and innovation can thrive. We look forward to celebrating the breakthroughs and successes that this initiative enables." Ronan Rogers, Senior R&D Director, Medtronic, said: "Today's launch of the Medical Device Prototype Hub represents an exciting next step in our long?standing partnership with the University of Galway. Medtronic has deep roots in the west of Ireland, and this facility strengthens a shared commitment to advancing research, accelerating innovation, and developing the next generation of medical technologies. We are proud to invest in an ecosystem that not only drives technological progress but also supports talent development. This Hub will unlock new avenues for discovery and accelerate the path from promising ideas to real?world medical solutions for patients." The Medical Device Prototype Hub forms part of the Institute for Health Discovery and Innovation, which was established in the University in 2024, as part of the signature innovation partnership. It will be further supported through collaborations with government agencies and industry leaders. The Medical Device Prototype Hub sits within the University of Galway's new Technology Services Directorate, which provides shared research infrastructure and technical expertise to underpin activities across both the Institute for Health Discovery and Innovation and the Institute for Clinical Trials, established in 2024 and 2023, respectively. The Hub will be further enhanced through partnerships with government agencies and industry leaders, creating a collaborative environment that supports translation, innovation, and regional growth in life sciences and medical technologies. The development is part of an integrated ecosystem at the University of Galway, which enables sustained, research-led development, further positioning Galway as the centre of Ireland's global MedTech hub and the University as integral to research for the public good on the world stage. Aoife Duffy, Director of Technology Services Directorate at University of Galway, said: "The Technology Services Directorate brings together key research facilities that support fundamental research at University of Galway. It aims to advance our research excellence by bringing together state-of-the-art core facilities and making strategic decisions on infrastructure and investment. The new prototype hub significantly enhances the innovation pathway available for the university research community and wider, and we look forward to working with Medtronic on this partnership". Professor Ted Vaughan, Director of Institute for Health Discovery and Innovation (IHDI), said: "The Medical Device Prototype Hub will serve as a central core facility, providing the engineering infrastructure and expertise to design, build and test new devices. It adds to the vibrant healthtech and medtech ecosystem in the west of Ireland and provides fertile ground to drive its growth. "Our vision is to make sure we have the best possible conditions for the R&D of new technologies for healthcare. Our aim is to address remaining gaps in the development pipeline, from discovery to innovation." The Medical Device Prototype Hub has expert staff to facilitate concept c...

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want to help patients know their options. Patients who turn to us either have no treatment options for their conditions or have exhausted the treatment options. They are looking for alternatives and insights into whether we can help them find, for example, a clinical trial. Physicians who treat those patients turn to us."  "And last but not least, we work with biopharma companies that plan and conduct clinical trials and that sponsor expanded access programs. And those are our clients. So we connect all of those stakeholders. In addition, we work very closely with representative groups of patients and patient advocacy groups to make sure that we are known and to make sure that we understand what specific patient groups might need from companies like ours. So we kind of connect the dots, I guess, and an otherwise somewhat siloed system sometimes, and consider ourselves a platform player. Think of us a little bit like, let's say, booking.com for clinical trials." #myTomorrows #ClinicalTrials #HealthTech #PatientAccess #RareDiseases #DigitalHealth #Healthcare #Innovation #AI #PatientEmpowerment #Biotechnology #Pharma #MedicalResearch #HealthcareEquity #Technology mytomorrows.com Download the transcript here

Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want to help patients know their options. Patients who turn to us either have no treatment options for their conditions or have exhausted the treatment options. They are looking for alternatives and insights into whether we can help them find, for example, a clinical trial. Physicians who treat those patients turn to us."  "And last but not least, we work with biopharma companies that plan and conduct clinical trials and that sponsor expanded access programs. And those are our clients. So we connect all of those stakeholders. In addition, we work very closely with representative groups of patients and patient advocacy groups to make sure that we are known and to make sure that we understand what specific patient groups might need from companies like ours. So we kind of connect the dots, I guess, and an otherwise somewhat siloed system sometimes, and consider ourselves a platform player. Think of us a little bit like, let's say, booking.com for clinical trials." #myTomorrows #ClinicalTrials #HealthTech #PatientAccess #RareDiseases #DigitalHealth #Healthcare #Innovation #AI #PatientEmpowerment #Biotechnology #Pharma #MedicalResearch #HealthcareEquity #Technology mytomorrows.com Listen to the podcast here

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, sit down with Mary (Maru) Rinella, MD, a professor of medicine and director of Clinical Trials and the Metabolic and Fatty Liver Program at the University of Chicago, to discuss the rapidly evolving therapeutic landscape for metabolic dysfunction-associated steatohepatitis (MASH).Key Episode Timestamps:0:00:00 – Introduction & guest bio0:01:02 – Current therapy landscape & GLP‑1 overview0:03:51 – Do GLP‑1s help non–weight losers?0:05:21 – Combining GLP‑1s and resmetirom0:07:23 – Pipeline GLP‑1 combinations & phase 2 data0:09:26 – Advanced disease, sarcopenia & risk–benefit in cirrhosis0:13:29 – Introduction to FGF‑21 agonists0:14:04 – Symmetry (efruxifermin) trial & reading the data0:17:51 – Endpoints, “lack of progression,” and FDA hurdles0:19:41 – Need for non‑invasive surrogates0:21:02 – FGF‑21 mechanism & other liver diseases0:22:57 – Alcohol intake, GLP‑1s, FGF‑21 & MetALD0:25:49 – 10‑year outlook & future toolbox0:27:35 – Closing

The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.

Meet Abdul Rastagar, Head of Marketing at Lexitas Pharma Services, a CRO specializing in ophthalmology clinical trials. Abdul shares his expertise on pharmaceutical marketing, emphasizing the importance of brand awareness and targeted content for lead generation. He also discusses the crucial role of LinkedIn and website development in client acquisition, highlighting the significance of website accessibility in the digital age.

Misinformation still finds its way into the conversation. Dorothy Gibbons and Dr. Raz dive into breast cancer myths, mammogram safety, risk factors, and common social media claims. They sort through concerns about bras, deodorants, cell phones, diet, and trauma. Evidence and screening guidelines guide the facts during this episode. Please consider sharing this episode, or making a donation at therose.org so more women receive breast cancer screening and care. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. Does getting a mammogram increase your risk of developing breast cancer due to radiation exposure? 2. Why is there so much controversy and skepticism surrounding mammograms and breast cancer screening, especially compared to other screenings? 3. Is breast cancer only a concern for women with a family history of the disease? 4. Is breast cancer purely an older woman’s disease, or can younger women get it too? 5. Does wearing an underwire bra or any bra cause breast cancer? 6. Can deodorant use (especially with aluminum) lead to breast cancer? 7. Is carrying a cell phone in your bra (or close to your body) a cause of breast cancer? 8. Does hair dye or using plastic water bottles increase breast cancer risk? 9. Does hormone replacement therapy (HRT) increase breast cancer risk? 10. Can breast injury or trauma cause breast cancer? 11. Does obesity relate to breast cancer risk? 12. Can animals sense breast cancer in humans? 13. Are alternative treatments or internet trends (like ivermectin or bee venom) effective against breast cancer? 14. Is it important for patients to trust their doctor and treatment process? Timestamped Overview 00:00 Mammogram Radiation: Safe and Essential 04:22 Annual Screening Controversy Explained 08:28 Breast Cancer: Risks and Incidence 11:14 Impact of Treating Women's Diseases 13:52 Aluminum in Deodorant Safe 18:29 HRT Risks and Tapering Explained 25:52 Ivermectin Misuse and Clinical Trials 28:51 Health's Role in Cancer Prevention 29:47 Poison Necessary to Fight CancerSee omnystudio.com/listener for privacy information.

Marking an important milestone for this rare form of retinitis pigmentosa (RP)

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health's CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB

In the third installment of the Skin Anarchy and Timeline Masterclass, Dr. Ekta Yadav sits down with Dr. Brad Currier, Manager of Clinical Trials at Timeline, for a behind-the-scenes look at what real evidence in longevity science and skincare actually requires.With a foundation in muscle physiology, exercise science, and aging research, Dr. Currier brings a performance-driven lens to longevity — reframing skin not as a cosmetic surface, but as a mitochondria-dense longevity organ, biologically linked to muscle health, metabolic resilience, and cellular energy. The episode explores why mitochondrial function may be one of the most underappreciated drivers of how both skin and the body age.At the center of the conversation is Timeline's research on urolithin A, a postbiotic shown to support mitochondrial renewal. Rather than relying on marketing narratives, Timeline has built its platform on mechanism-first science, translating years of cellular research into human clinical trials — including biopsy-based studies that reveal measurable changes in collagen synthesis and skin structure.Dr. Currier also pulls back the curtain on the truth about clinical claims in beauty — explaining why many “clinically tested” labels lack rigor, how underpowered or biased studies distort results, and what separates meaningful, published human data from perception-based marketing. From wrinkle depth to hydration to barrier function, he outlines how Timeline measures outcomes that reflect real biological change — not just surface-level improvement.The episode ultimately reframes longevity as precision science, not hype — emphasizing the importance of human trials, mitochondrial health, and transparent evidence in an industry flooded with buzzwords.Listen to the full episode of Skin Anarchy to hear Dr. Brad Currier unpack what clinical validation should look like — and why the future of longevity skincare depends on measurable biology, not marketing promises.SHOP TIMELINEDon't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf!Support the show

The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Officer, joins me to explain what MS prevention looks like and how experts plan to achieve this remarkable goal. We'll also tell you who won the 2025 Barancik Prize for Innovation in MS Research, and we'll explain how their groundbreaking research impacts MS care. We're sharing the details of a newly announced partnership designed to reduce delays in getting an MS diagnosis and expand access to MS care in Wisconsin. We'll tell you how an international drug discovery network found that a drug already approved for another condition could also protect nerve cells and promote remyelination. And we'll share research that shows that AI can accurately predict whether someone newly diagnosed with MS will experience progression independent of relapse activity (PIRA) in the three years following their diagnosis. We have a lot to talk about! Are you ready for RealTalk MS??! I'm asking for your support:  :22 This Week: Preventing MS  1:47 Dr. Manuel Friese is the winner of the 2025 Barancik Prize for Innovation in MS Research  2:41 National MS Society announces a partnership to improve time to MS diagnosis and access to MS care in Wisconsin  6:26 An international drug discovery network identifies a drug that protects nerve cells and promotes remyelination  8:05 STUDY: AI accurately predicts progression independent of relapse activity in individuals who are newly diagnosed with MS  10:51 Dr. Bruce Bebo explains the strategy behind the global research initiative to prevent MS  14:48 Share this episode  31:31 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/439 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms RealTalk MS Episode 424: I'm a Participant in a Clinical Trial for CAR T-Cell Therapy for MS with Jan Janisch-Hanzlik https://realtalkms.com/424 STUDY: In Silico Screening and Preclinical Validation Identify Bavisant as a Therapeutic Candidate for Multiple Sclerosis https://science.org/doi/10.1126/scitranslmed.ads0633 STUDY: Machine Learning Analysis Applied to Prediction of Early Progression Independent of Relapse Activity in Multiple Sclerosis Patients https://onlinelibrary.wiley.com/doi/10.1111/ene.70417 Find out about ABLEnow Accounts https://ablenow.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 439 Guests: Dr. Bruce Bebo Privacy Policy

Send us a textDr. Michael Koren joins Kevin Geddings to offer the solace of taking control of your medical future in these uncertain times. The doctor reminds listeners that when news is stressful and chaotic, doing things that impact you and your life can help reduce anxiety. He suggests that taking advantage of free screening exams at clinical research sites may help people make sense of the otherwise mysterious and can help find solutions to problems they weren't even aware of.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for building trust and improving accessibility. Sarah explains, "Behavioral science is about understanding behavior. It draws from a number of disciplines like psychology, anthropology, and behavioral economics. But what it tells us is that people aren't rational. They don't always do the things that we expect them to do. So if we want to engage people, if we want to engage them properly, if we want to ensure that all the things we do are equitable and have an equal playing field, then we need to really understand why people do the things they do and to try and help us make sense of that in a way that encompasses everybody."   "We see treatment and technology advancing, but there are many communities that aren't part of that still, that are underrepresented. Factors like gender, ethnicity, culture, conditions that carry a stigma, socioeconomic issues, and geographic limitations - all of these things can limit the opportunity, ability, and willingness of individuals to participate in clinical trials. And that means the impact of those trials is less generalizable because those people are not represented. They're just simply not there. So the treatment that is aimed at these people is not measured in those groups. Oracle is working to address this by combining a deeper understanding of behavior with integrated technology to try to close this gap in representation to give more inclusive patient-centered care that unifies clinical, behavioral, and safety data across settings. To give a more holistic view, to give more coordinated care, to identify risks earlier, to identify patients that perhaps just need a bit more attention - a more personalized engagement."   #OracleLifeSciences #lifesciences #ClinicalResearch #PatientCentricity #PatientEngagement #ClinicalTrials #Healthliteracy #BehavioralScience #HealthEquity #AI #Healthcare #Diversity #Inclusion #MedicalResearch #Innovation Oracle.com/life-sciences  Download the transcript here  

Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for building trust and improving accessibility. Sarah explains, "Behavioral science is about understanding behavior. It draws from a number of disciplines like psychology, anthropology, and behavioral economics. But what it tells us is that people aren't rational. They don't always do the things that we expect them to do. So if we want to engage people, if we want to engage them properly, if we want to ensure that all the things we do are equitable and have an equal playing field, then we need to really understand why people do the things they do and to try and help us make sense of that in a way that encompasses everybody."   "We see treatment and technology advancing, but there are many communities that aren't part of that still, that are underrepresented. Factors like gender, ethnicity, culture, conditions that carry a stigma, socioeconomic issues, and geographic limitations - all of these things can limit the opportunity, ability, and willingness of individuals to participate in clinical trials. And that means the impact of those trials is less generalizable because those people are not represented. They're just simply not there. So the treatment that is aimed at these people is not measured in those groups. Oracle is working to address this by combining a deeper understanding of behavior with integrated technology to try to close this gap in representation to give more inclusive patient-centered care that unifies clinical, behavioral, and safety data across settings. To give a more holistic view, to give more coordinated care, to identify risks earlier, to identify patients that perhaps just need a bit more attention - a more personalized engagement."   #OracleLifeSciences #lifesciences #ClinicalResearch #PatientCentricity #PatientEngagement #ClinicalTrials #Healthliteracy #BehavioralScience #HealthEquity #AI #Healthcare #Diversity #Inclusion #MedicalResearch #Innovation Oracle.com/life-sciences  Listen to the podcast here  

What happens when decades of clinical research experience collide with a regulatory environment that is changing faster than ever? In this episode of Tech Talks Daily, I sat down with Dr Werner Engelbrecht, Senior Director of Strategy at Veeva Systems, for a wide-ranging conversation that explores how life sciences organizations across Europe are responding to mounting regulatory pressure, rapid advances in AI, and growing expectations around transparency and patient trust. Werner brings a rare perspective to this discussion. His career spans clinical research, pharmaceutical development, health authorities, and technology strategy, shaped by firsthand experience as an investigator and later as a senior industry leader.  That background gives him a grounded, practical view of what is actually changing inside pharma and biotech organizations, beyond the headlines around AI Acts, data rules, and compliance frameworks. We talk openly about why regulations such as GDPR, the EU AI Act, and ACT-EU are creating real pressure for organizations that are already operating in highly controlled environments. But rather than framing compliance as a blocker, Werner explains why this moment presents an opening for better collaboration, stronger data foundations, and more consistent ways of working across internal teams. According to him, the real challenge is less about technology and more about how companies manage data quality, align processes, and break down silos that slow everything from trial setup to regulatory response times. Our conversation also digs into where AI is genuinely making progress today in life sciences and where caution still matters. Werner shares why drug discovery and non-patient-facing use cases are moving faster, while areas like trial execution and real-world patient data still demand stronger evidence, cleaner datasets, and clearer governance. His perspective cuts through hype and focuses on what is realistic in an industry where patient safety remains the defining responsibility. We also explore patient recruitment, decentralized trials, and the growing complexity of diseases themselves. Advances in genomics and diagnostics are reshaping how trials are designed, which in turn raises questions about access to electronic health records, data harmonization across Europe, and the safeguards regulators care about most. Werner connects these dots in a way that highlights both the operational strain and the long-term upside. Toward the end, we look ahead at emerging technologies such as blockchain and connected devices, and how they could strengthen data integrity, monitoring, and regulatory confidence over time. It is a thoughtful discussion that reflects both optimism and realism, rooted in lived experience rather than theory. If you are working anywhere near clinical research, regulatory affairs, or digital transformation in life sciences, this episode offers a clear-eyed view of where the industry stands today and where it may be heading next. How should organizations turn regulation into momentum instead of resistance, and what will it take to earn lasting trust from patients, partners, and regulators alike? Useful Links Connect with Dr Werner Engelbrecht Learn more about Veeva Systems Viva Summit Europe and Viva Summit USA Follow on LinkedIn Thanks to our sponsors, Alcor, for supporting the show.

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.